‘Our data is resonating far more with the people that matter,’ Bicara CEO says amid Merus race
Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell carcinoma (HNSCC). But the chase is still in its early days and is likely too soon to call.
Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell carcinoma (HNSCC). But the chase is still in its early days and is likely too soon to call.
